Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

85.02 +0.43 (+0.51%)
Streaming Delayed Price Updated: 9:34 AM EDT, Oct 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,679
Open 84.59
Bid (Size) 84.72 (2)
Ask (Size) 84.83 (2)
Prev. Close 84.59
Today's Range 84.62 - 85.02
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 3.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga

Performance

YTD
+2.14%
+2.14%
1 Month
+8.00%
+8.00%
3 Month
+25.86%
+25.86%
6 Month
+22.47%
+22.47%
1 Year
+13.27%
+13.27%

More News

Read More
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
Via Benzinga
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
From Gilead Sciences, Inc.
Via Business Wire
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
Via Benzinga
News Is Noise
Via Talk Markets
Top 4 Health Care Stocks That May Keep You Up At Night
Via Benzinga
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
Via Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
Via The Motley Fool
Gilead Sciences Unusual Options Activity For September 20
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Via Benzinga
What the Options Market Tells Us About Gilead Sciences
Via Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Why Gilead Sciences Stock Thrashed the Market Today
Via The Motley Fool
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
From Gilead Sciences, Inc.
Via Business Wire
Biotech Breakout: Stocks for Your Watchlist
Via MarketBeat
Topics ETFs
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
From Gilead Sciences, Inc.
Via Business Wire
Four Stocks To Watch This Week - Monday, Sept 9
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.